Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

INVO Fertility (IVF) Total Liabilities (2016 - 2025)

INVO Fertility (IVF) has disclosed Total Liabilities for 15 consecutive years, with $13.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Liabilities fell 23.82% to $13.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $13.0 million, a 23.82% decrease, with the full-year FY2024 number at $26.2 million, up 49.01% from a year prior.
  • Total Liabilities was $13.0 million for Q3 2025 at INVO Fertility, down from $16.7 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $26.2 million in Q4 2024 to a low of $2.5 million in Q1 2022.
  • A 5-year average of $11.0 million and a median of $6.6 million in 2023 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: tumbled 49.13% in 2022, then surged 459.65% in 2023.
  • INVO Fertility's Total Liabilities stood at $2.7 million in 2021, then surged by 74.69% to $4.7 million in 2022, then soared by 275.75% to $17.6 million in 2023, then surged by 49.01% to $26.2 million in 2024, then tumbled by 50.53% to $13.0 million in 2025.
  • Per Business Quant, the three most recent readings for IVF's Total Liabilities are $13.0 million (Q3 2025), $16.7 million (Q2 2025), and $24.4 million (Q1 2025).